205 related articles for article (PubMed ID: 35176052)
1. Considerations and practical implications of performing a phenotypic CRISPR/Cas survival screen.
Ashoti A; Limone F; van Kranenburg M; Alemany A; Baak M; Vivié J; Piccioni F; Dijkers PF; Creyghton M; Eggan K; Geijsen N
PLoS One; 2022; 17(2):e0263262. PubMed ID: 35176052
[TBL] [Abstract][Full Text] [Related]
2. Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.
Lek A; Zhang Y; Woodman KG; Huang S; DeSimone AM; Cohen J; Ho V; Conner J; Mead L; Kodani A; Pakula A; Sanjana N; King OD; Jones PL; Wagner KR; Lek M; Kunkel LM
Sci Transl Med; 2020 Mar; 12(536):. PubMed ID: 32213627
[TBL] [Abstract][Full Text] [Related]
3. A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4.
Sasaki-Honda M; Jonouchi T; Arai M; Hotta A; Mitsuhashi S; Nishino I; Matsuda R; Sakurai H
Hum Mol Genet; 2018 Dec; 27(23):4024-4035. PubMed ID: 30107443
[TBL] [Abstract][Full Text] [Related]
4. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy.
Himeda CL; Jones TI; Jones PL
Mol Ther; 2016 Mar; 24(3):527-35. PubMed ID: 26527377
[TBL] [Abstract][Full Text] [Related]
6. CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy.
Das S; Chadwick BP
Sci Rep; 2021 Jun; 11(1):12598. PubMed ID: 34131248
[TBL] [Abstract][Full Text] [Related]
7. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
Haynes P; Bomsztyk K; Miller DG
Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
[TBL] [Abstract][Full Text] [Related]
8. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones PL
Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108
[TBL] [Abstract][Full Text] [Related]
9. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
Banerji CRS; Panamarova M; Zammit PS
Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
[TBL] [Abstract][Full Text] [Related]
10. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
[TBL] [Abstract][Full Text] [Related]
11. Direct interplay between two candidate genes in FSHD muscular dystrophy.
Ferri G; Huichalaf CH; Caccia R; Gabellini D
Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
[TBL] [Abstract][Full Text] [Related]
12. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
13. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
14. Deciphering transcription dysregulation in FSH muscular dystrophy.
Ehrlich M; Lacey M
J Hum Genet; 2012 Aug; 57(8):477-84. PubMed ID: 22718021
[TBL] [Abstract][Full Text] [Related]
15. Intronic
Goossens R; van den Boogaard ML; Lemmers RJLF; Balog J; van der Vliet PJ; Willemsen IM; Schouten J; Maggio I; van der Stoep N; Hoeben RC; Tapscott SJ; Geijsen N; Gonçalves MAFV; Sacconi S; Tawil R; van der Maarel SM
J Med Genet; 2019 Dec; 56(12):828-837. PubMed ID: 31676591
[TBL] [Abstract][Full Text] [Related]
16. DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis.
Young JM; Whiddon JL; Yao Z; Kasinathan B; Snider L; Geng LN; Balog J; Tawil R; van der Maarel SM; Tapscott SJ
PLoS Genet; 2013 Nov; 9(11):e1003947. PubMed ID: 24278031
[TBL] [Abstract][Full Text] [Related]
17. Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy.
DeSimone AM; Leszyk J; Wagner K; Emerson CP
Sci Adv; 2019 Dec; 5(12):eaaw7099. PubMed ID: 31844661
[TBL] [Abstract][Full Text] [Related]
18. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
19. A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death.
Bosnakovski D; da Silva MT; Sunny ST; Ener ET; Toso EA; Yuan C; Cui Z; Walters MA; Jadhav A; Kyba M
Sci Adv; 2019 Sep; 5(9):eaaw7781. PubMed ID: 31535023
[TBL] [Abstract][Full Text] [Related]
20. DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy.
Shadle SC; Zhong JW; Campbell AE; Conerly ML; Jagannathan S; Wong CJ; Morello TD; van der Maarel SM; Tapscott SJ
PLoS Genet; 2017 Mar; 13(3):e1006658. PubMed ID: 28273136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
